- Home
- CNSP vs EDSA Comparison
CNSP vs EDSA Comparison
Compare CNSP & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNSP
- EDSA
- Stock Information
- Founded
- CNSP 2017
- EDSA 2015
- Country
- CNSP United States
- EDSA Canada
- Employees
- CNSP N/A
- EDSA N/A
- Industry
- CNSP Biotechnology: Pharmaceutical Preparations
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- CNSP Health Care
- EDSA Health Care
- Exchange
- CNSP Nasdaq
- EDSA Nasdaq
- Market Cap
- CNSP 5.4M
- EDSA 6.1M
- IPO Year
- CNSP 2019
- EDSA N/A
- Fundamental
- Price
- CNSP $0.11
- EDSA $1.90
- Analyst Decision
- CNSP Strong Buy
- EDSA Strong Buy
- Analyst Count
- CNSP 1
- EDSA 1
- Target Price
- CNSP $0.50
- EDSA $21.00
- AVG Volume (30 Days)
- CNSP 6.2M
- EDSA 31.2K
- Earning Date
- CNSP 11-15-2024
- EDSA 02-07-2025
- Dividend Yield
- CNSP N/A
- EDSA N/A
- EPS Growth
- CNSP N/A
- EDSA N/A
- EPS
- CNSP N/A
- EDSA N/A
- Revenue
- CNSP N/A
- EDSA N/A
- Revenue This Year
- CNSP N/A
- EDSA N/A
- Revenue Next Year
- CNSP N/A
- EDSA N/A
- P/E Ratio
- CNSP N/A
- EDSA N/A
- Revenue Growth
- CNSP N/A
- EDSA N/A
- 52 Week Low
- CNSP $0.10
- EDSA $1.69
- 52 Week High
- CNSP $71.00
- EDSA $5.99
- Technical
- Relative Strength Index (RSI)
- CNSP 49.04
- EDSA 37.11
- Support Level
- CNSP $0.10
- EDSA $1.73
- Resistance Level
- CNSP $0.12
- EDSA $2.55
- Average True Range (ATR)
- CNSP 0.01
- EDSA 0.18
- MACD
- CNSP 0.00
- EDSA 0.03
- Stochastic Oscillator
- CNSP 56.90
- EDSA 25.58
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.